Related Experiment Video
Updated: Dec 3, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
Favipiravir use for SARS CoV-2 infection
1Prince Mohammad Bin Fahd University, PO Box 1664, Al Khobar, 31952, Kingdom of Saudi Arabia. deanshipofresearch@pmu.edu.sa.
Introduction:
The pandemic of SARS CoV-2 has required urgent medical treatments for numerous patients. As no specific antiviral agents were available, different off-the-shelf alternatives have been explored.
Objective:
Here, we review the rationale behind the use of Favipiravir, and report of the specific studies supporting this treatment being conducted.
Methods:
Here we analyze the relevant literature to conclude about the present opportunities offered by this therapeutic agent.
Results:
This antiviral drug approved influenza in Japan since 2014, has a demonstrated in vitro activity against SARS CoV-2 and is being investigated in several trials for SARS CoV-2. Signals of benefit were shown in a small trial for SARS CoV-2. However, in another small study, there was no advantage.
Conclusions:
Further studies, statistically more significant, are urgently needed to understand the best opportunities offered by this treatment.
Related Concept Videos
Subviral Agents
Acute Respiratory Failure-IV
Acute Respiratory Failure-II
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:

